Working with a mutant of the serpin α1-antichymotrypsin, researchers have designed a way of preventing misfolding while leaving the anti-proteolytic effect unabated.

TOP INSIGHT
A group of rare heritable diseases known as "serpinopathies" are caused by mutations of so-called "serpin" inhibitors of proteolytic enzymes involved in blood coagulation, tissue remodeling, and other important physiological functions.
A long standing problem has been that agents preventing misfolding also inhibit the anti-proteolytic functions of the serpins. Working with a mutant of the serpin α1-antichymotrypsin, a group of Danish researchers has now designed a way of preventing misfolding while leaving the anti-proteolytic effect unabated. The α1-antichymotrypsin mutation is associated with chronic obstructive pulmonary disease (COPD).
The researchers have developed an RNA aptamer, which prevents misfolding and polymerisation of the α1-antichymotrypsin mutant and does not interfere with its ability to inhibit the target proteases, i.e., cathepsin G and chymotrypsin. One perspective is that similar strategies may be employed by other proteins prone to misfolding.
The results have been published in Cell Chem. Biol. An RNA aptamer preserving full activity of a pathogenic serpin mutant. Madsen, J.B., Andersen, L.M., Dupont, D.M., Trelle, M.B., Johansen, J.S., Jensen, J.K., Jørgensen, T.J.D., and Andreasen, P.A. (2016) Cell Chem. Biol.).
The work was done in a collaboration between scientists from the Department of Molecular Biology and Genetics, Aarhus University, and the Department of Biochemistry and Molecular Biology at the University of Southern Denmark. The project, headed by Peter A. Andreasen, has been supported by the Danish Research Council for Technology and Production with DKK 14.1 million. The project has already resulted in several biochemical and structural biology publications, but with the article in Cell Chem. Biol., the main purpose of the project has been accomplished.
MEDINDIA




Email






